The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. [electronic resource]
Producer: 20080721Description: 584-91 p. digitalISSN:- 1468-3296
- Adult
- Anti-Asthmatic Agents -- therapeutic use
- Anti-Inflammatory Agents, Non-Steroidal -- therapeutic use
- Asthma -- drug therapy
- Biomarkers -- blood
- Bronchial Hyperreactivity -- physiopathology
- Double-Blind Method
- Drug Resistance
- Etanercept
- Female
- Forced Expiratory Volume -- drug effects
- Humans
- Immunoglobulin G -- therapeutic use
- Male
- Middle Aged
- Quality of Life
- Receptors, Tumor Necrosis Factor -- therapeutic use
- Sputum -- chemistry
- Surveys and Questionnaires
- Treatment Outcome
- Vital Capacity -- drug effects
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.